drugset
drugset / Trial / NCT05238844

A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection

NCT05238844 ↗

Phase 2 Terminated 2 enrolled Antios Therapeutics, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in volunteers with chronic hepatitis B virus infection. Volunteers will be administered multiple oral doses of ATI-2173 vebicorvir in combination with tenofovir disoproxil fumarate and assessed for safety and efficacy including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the drug effects the virus infection.

Timeline

Start
2022-04-11
Primary completion
2022-05-25
Completion
2022-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject FOSCLEVUDINE ALAFENAMIDE Other / unclassified 25 mg Oral
Subject Vebicorvir Small molecule 300 mg Oral
Background Tenofovir disoproxil fumarate Small molecule 300 mg Oral

Indications

chronic hepatitis B virus infection